A Phase 1 Study to Evaluate the Safety, Tolerability and Immunogenicity of Heterologous Prime-Boost Regimens Using MVA-BN-Filo and Ad26.ZEBOV Administered in Different Sequences and Schedules in Healthy Adults

Trial Profile

A Phase 1 Study to Evaluate the Safety, Tolerability and Immunogenicity of Heterologous Prime-Boost Regimens Using MVA-BN-Filo and Ad26.ZEBOV Administered in Different Sequences and Schedules in Healthy Adults

Completed
Phase of Trial: Phase I

Latest Information Update: 13 Dec 2016

At a glance

  • Drugs Ad26 EBOV vaccine (Primary) ; Modified Vaccinia Ankara Bavarian Nordic Ebola Marburg vaccine (Primary)
  • Indications Ebola virus infections; Marburg virus disease
  • Focus Adverse reactions
  • Sponsors Crucell Holland
  • Most Recent Events

    • 07 Dec 2016 Status changed from active, no longer recruiting to completed.
    • 22 Jan 2016 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
    • 17 Dec 2015 Planned number of patients changed from 84 to 72, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top